BUY Sun Pharmaceutical Industries Ltd. — Arpit Beriwal, Motilal Oswal
byArpit Beriwal, Motilal OswalHorizon: NA (inferred Swing (≤2wk))6 Aug 2026via ET Now
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
3 other SEBI-registered advisors have active swing BUY calls on this stock, all issued in the last 14 days
Advisor consensus · same horizon·19 Aug · today
Sun Pharma and its subsidiaries have won an antitrust litigation in the US related to the Lipitor patent settlement. The US Court of Appeals affirmed a summary judgment in their favor, denying class c
BSE · Company Update·17 Aug · 3d ago
Sun Pharma has received approval to manufacture and market semaglutide in Brazil, indicating a potential market expansion and new product offering.
BSE · Company Update·29 Jul · 3w ago
3 advisors have active short-term BUY calls on this stock
Advisor consensus · adjacent horizon·30 Jul · 3w ago
Sun Pharma announced that Organon shareholders have approved the proposed acquisition, moving forward the company's strategic expansion plans.
BSE · Company Update·24 Jul · 4w ago
CRISIL has removed the 'Rating Watch with Developing Implications' status and reaffirmed Sun Pharma's long-term bank facilities rating at 'CRISIL AAA/Stable'.
BSE · Company Update·5 Aug · 2w ago
Unaudited Standalone and Consolidated Financial Results for Q1 of FY 2026-27
NSE · Outcome of Board Meeting·31 Jul · 3w ago
Nothing found in this tip’s window yet.
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.